Revolutionary Stroke Diagnostic Solutions Drive Investment Growth
Stroke is the second-leading cause of death and the third-leading cause of combined death and disability worldwide. Despite continued prevention efforts, stroke incidence is rising. Rapid and accurate diagnosis remains essential to enable effective treatment before irreversible brain injury or loss of life occurs.
Our Innovative Solution
Galaxy CCRO is developing a point-of-care blood test designed to determine stroke onset, expanding access to time-sensitive thrombolytic therapies such as TPA for a broader patient population.
Why Invest in Galaxy CCRO?
Clinical Advancement
More than 15 million strokes occur each year globally, creating sustained demand for fast, reliable diagnostic technologies.
Strategic Partnerships
We have secured a licensing agreement with Proteome Sciences, leveraging advanced capabilities in proteomics and biomarker science.
Experienced Leadership
Our leadership team brings extensive expertise in emergency medicine, proteomics, clinical research, and business development, positioning the company for successful execution and growth.
Our Investment Opportunities
Invest in the future of stroke care. Supporting Galaxy CCRO means advancing life-saving diagnostics, improving outcomes, and making a measurable impact on global health.